On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
ISMPP U webinar: insights and perspectives on open access in medical publishing
Last week’s ISMPP-U webinar ‘Open Access and Medical Publishing’, developed by the Medical Publishing Insights & Practices (MPIP) initiative and Open Pharma and moderated by LaVerne Mooney (Pfizer) and Chris Winchester (Oxford PharmaGenesis), aimed to define the key elements of open access policies, to provide insight into the changing publishing environment and to understand the perspectives of non-commercial and commercial stakeholders on open access publishing.
Guest post: How to make research open to everybody: a case study on ecancer
In recent years, open access has provided new audiences, including patients, the general public and doctors in low and middle income countries (LMICs), with direct, free access to the results of scientific research.
Increasing transparency in biomedical research: CBMRT
In order to protect the quality of clinical research it is vital for all trials to be represented in scientific literature for the benefit of scientific progress and research efficiency, and, ultimately, to better inform care for our patients in a timely manner.
How Crossref can help medical publishing professionals
CrossRef is a nonprofit whose goal is to catalogue metadata about scholarly works in order to facilitate easier access and correct record keeping--and they might just become medical publishers’ new best friend.
Cultivating ORCID at the Royal Society
Based on our experience, we believe that ORCID can make medical publishing faster and more transparent.
Tools supporting ethics and integrity in submission and review
With CRediT, ORCID and Publons integrated into Editorial Manager®, we aim for these transparency tools to be easy, standard steps in the publishing process
Bold attempt at studying open peer review flops badly
Personal commentary from Richard Smith, chair of Open Pharma